Ranitidine

Generic Name: Ranitidine

Brand Names: Good Sense Acid Reducer, Wal-zan, Zantac

Drug Type: Small Molecule

Chemical Formula: C_₁₃H_₂₂N_₄O_₃S

CAS Number: 66357-35-5

Unique Ingredient Identifier: 884KT10YB7

Background: Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as cimetidine and famotidine. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion. Ranitidine is often referred to as Zantac, and is available...

Indication: This drug is used alone or with concomitant antacids for the following conditions: short-term treatment of active duodenal ulcer, treating gastric acid hypersecretion due to Zollinger-Ellison syndrome, systemic mastocytosis, and other conditions that may pathologically raise gastric acid levels. It also used in the short term treatment of active benign gastr...

Associated Conditions: Acid Aspiration Syndrome, Ankylosing Spondylitis (AS), Duodenal Ulcer, Erosive Esophagitis, Gastric Ulcer, Gastric hypersecretion, Gastro-esophageal Reflux Disease (GERD), Healing, Heartburn, Osteoarthritis (OA), Peptic Ulcer Disease, Rheumatoid Arthritis, Stress Ulcers, Zollinger-Ellison Syndrome, Active Duodenal ulcer, Benign gastric ulcer healing, Benign gastric ulcers, Duodenal ulcer healing, Post-operative peptic ulcer, Recurrent hemorrhage from bleeding ulcers

Associated Therapies: -

Clinical Trials

Effect of Single Doses of YF476 on Stomach Acidity Compared With Ranitidine and Placebo in Fasted and Fed States

Phase 1

Completed

Conditions: Reflux Oesophagitis

First Posted Date: 2012-02-24

Last Posted Date: 2012-02-24

Lead Sponsor: Trio Medicines Ltd.

Target Recruit Count: 22

Registration Number: NCT01538797

Locations: 🇬🇧
Hammersmith Medicines Research, London, United Kingdom

A Study to Evaluate The Effects of Two Different Meal Types, Omeprazole And Ranitidine On Danoprevir Pharmacokinetics When Coadministered With Ritonavir in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: danoprevir
Drug: omeprazole
Drug: ritonavir
Drug: ranitidine

First Posted Date: 2011-07-12

Last Posted Date: 2016-11-02

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 32

Registration Number: NCT01392755

TPI 287 in Breast Cancer Metastatic to the Brain

Phase 2

Completed

Conditions: Breast Cancer

Interventions: Drug: TPI 287
Drug: Dexamethasone
Drug: Benadryl
Drug: Ranitidine

First Posted Date: 2011-04-11

Last Posted Date: 2018-09-20

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 24

Registration Number: NCT01332630

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Bioequivalency Study of Ranitidine Tablets 300 mg of Dr. Reddy's Under Fasting Conditions

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Ranitidine

First Posted Date: 2010-05-27

Last Posted Date: 2010-06-09

Lead Sponsor: Dr. Reddy's Laboratories Limited

Target Recruit Count: 24

Registration Number: NCT01131702

Locations: 🇨🇦
Anapharm Inc., Montreal, Quebec, Canada

Rabeprazole Extended Release 50 mg Versus Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Phase 3

Completed

Conditions: Gastroesophageal Reflux Disease (GERD)

Interventions: Drug: Rabeprazole ER
Drug: Ranitidine

First Posted Date: 2009-02-09

Last Posted Date: 2016-02-08

Lead Sponsor: Eisai Inc.

Target Recruit Count: 240

Registration Number: NCT00839306

Locations: 🇺🇸
Midwest Clinical, Moline, Illinois, United States
🇺🇸
Associates, Ltd., Moline, Illinois, United States
🇺🇸
Research, Moline, Illinois, United States

Rabeprazole Extended-Release 50 mg vs. Ranitidine 150 mg for Maintenance of Healed Erosive Gastroesophageal Reflux Disease (GERD)

Phase 3

Completed

Conditions: Gastroesophageal Reflux Disease (GERD)

Interventions: Drug: Rabeprazole ER
Drug: Ranitidine

First Posted Date: 2009-02-06

Last Posted Date: 2022-04-25

Lead Sponsor: Eisai Inc.

Target Recruit Count: 240

Registration Number: NCT00838526

Locations: 🇺🇸
Ltd., Moline, Illinois, United States
🇺🇸
Research Associates, Moline, Illinois, United States
🇺🇸
Midwest Clinical, Moline, Illinois, United States